Considering all aspects mentioned above, we hypothesized that a nano-PROTAC capable of inducing an acute ROS induction specifically in the lung cancer tissue might be a potential strategy for these patients with wild type NRF2/KEAP1 signature. This evidence concerns the gene NFE2L2 and lung cancer.